Michael Keller, Senior Fellow, siRNA Project Leader, Technical Research and Development (TRD), **Novartis Pharma**

Michael Keller studied Biophysics/Chemistry at the *ETH* Zürich and Imperial College London from which he graduated with an MSc in 1995. Following his PhD obtained from the University of Lausanne specialising in peptide and protein Biochemistry, he was awarded a Swiss National Science Foundation Fellowship at Imperial College London where he diversified his interests in gene and siRNA delivery. He *co*-founded IC-Vec, an Imperial College spin-out company, in 2002 and was its Chief Scientist until the trade sale in 2006. He started his current position as Senior Fellow at Novartis Pharma AG Basel in 2007. His main focus at Novartis are the development of innovative drug delivery systems that include nanomedicines for parenteral and topical applications as well as active transdermal delivery systems. He received a "Novartis leading scientist 2009 award" for his contributions to the formulation and delivery of small interfering RNA (siRNA).